Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Intestinal Failure Panel Discussion at Pediatric Gastroenterology Conference in Abu Dhabi
Ongoing pediatric crofelemer investigations reported no significant clinical or laboratory abnormalities.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Jaguar Health (JAGX) announced that Napo Pharmaceuticals is sponsoring an intestinal failure panel in Abu Dhabi on October 30, 2026. The panel, titled Intestinal Barrier Beyond Total Parenteral Nutrition, is part of the 2nd Best of Elite Ped-GI meeting. Participants include Dr. Mohamad Miqdady, Dr. Christos Tzivinikos and Jaguar's chief scientific officer, Pravin Chaturvedi.
Ongoing studies of oral liquid crofelemer in children with intestinal failure showed reductions in weekly parenteral support needs and support normalized to body weight after more than one year of oral dosing. Parenteral support supplies nutrition or fluids intravenously. Jaguar plans a mid-2027 New Drug Application filing for microvillus inclusion disease.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.Jaguar plans a mid-2027 New Drug Application filing for microvillus inclusion disease.
- Minor pointOral liquid crofelemer investigations showed reduced weekly parenteral support needs in pediatric patients dosed for more than one year.
- Minor pointParenteral support normalized to body weight also declined in pediatric patients dosed orally for more than one year.
- Minor pointOngoing oral liquid crofelemer investigations reported no significant clinical or laboratory abnormalities.
Negative
- None.
Details
Market Reaction – JAGX
On Oct 6, the day this news came out, the latest delayed price for JAGX is 35.10% above the previous close. Our momentum scanner has recorded 49 alerts for this stock so far that day. The latest delayed price is $6.39. Relative volume is exceptionally heavy at 210.3x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Planned NDA filing
- Mid-2027
- MVID program
- Treatment duration
- More than one year
- Pediatric IF patients receiving oral liquid crofelemer
Key Terms
total parenteral nutrition medical
new drug application regulatory
microvillus inclusion disease medical
short bowel syndrome medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, CA / ACCESS Newswire / October 6, 2026 / Jaguar Health, Inc. (Nasdaq:JAGX) today announced that Jaguar family company Napo Pharmaceuticals (Napo) is a sponsor of the 2nd Best of Elite Ped-GI meeting in Abu Dhabi in the United Arab Emirates and is also sponsoring a panel discussion titled Intestinal Barrier Beyond Total Parenteral Nutrition (TPN) on October 30, 2026 at the meeting. Participants in the panel discussion include Dr. Mohamad Miqdady, Dr. Christos Tzivinikos, and Pravin Chaturvedi, PhD, Napo's and Jaguar's Chief Scientific Officer and Chair of the Scientific Advisory Board.
Dr. Miqdady is the Division Chief of the Pediatric Gastroenterology, Hepatology & Nutrition Division at Sheikh Khalifa Medical City, a flagship tertiary hospital in the UAE and the largest teaching medical center in Abu Dhabi. He is also a Clinical Professor at Khalifa University's medical school in Abu Dhabi, and completed his Fellowship in Pediatric Gastroenterology at Baylor College of Medicine and Texas Children's Hospital in Houston.
Dr. Christos Tzivinikos, MD DCH FRCPCH MSc CEBP, Chairman of the 2nd Best of Elite Ped-GI meeting, is a Consultant Pediatric Gastroenterologist and Founder of the Pediatric GI Department at Al Jalila Children's Specialty Hospital in Dubai, and Clinical Associate Professor at Mohammed Bin Rashid University of Medicine and Health Sciences in Dubai.
Napo remains sharply focused on its ongoing global development program for oral crofelemer as adjunctive therapy to parenteral support (PS) for rare IF diseases, including MVID and SBS-IF. In June 2026, as announced, data was presented at the 58th Annual European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN) Meeting in Lille, France from ongoing investigational studies with oral liquid crofelemer in pediatric patients with IF due to MVID and SBS-IF. The results of ongoing investigations of liquid oral crofelemer formulations demonstrate substantial reductions in weekly PS needs as well as in PS normalized to body weight in pediatric IF patients dosed orally for more than one year, with no significant clinical or laboratory abnormalities.
Jaguar's IF program is expected to continue to provide clinical milestones, including a planned New Drug Application (NDA) filing for MVID in mid-2027.
A recent Rareatives article shares the story of a young child living with MVID, highlighting the importance of family perspectives, supportive communication, and collaboration with clinicians in addressing rare intestinal diseases.
Dr. Miqdady is a member of Napo's Scientific Advisory Board. Dr. Miqdady and Dr. Tzivinikos are involved is clinical evaluations of crofelemer powder for oral solution for treatment of IF in pediatric IF patients.
The 2nd Best of Elite Ped-GI meeting is dedicated to advancing clinical knowledge and best practices in pediatric gastroenterology and nutrition, with a particular emphasis on parenteral nutrition in children with complex gastrointestinal disorders.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. Jaguar family companies Napo Pharmaceuticals, Inc. (Napo) and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including microvillus inclusion disease and short bowel syndrome.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that the company will file a New Drug Application (NDA) for crofelemer for MVID in mid-2027. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Jaguar Health's pediatric intestinal failure studies show for oral crofelemer?
Ongoing investigations showed reductions in weekly parenteral support needs and support normalized to body weight in pediatric patients dosed orally for more than one year. The studies involved intestinal failure due to microvillus inclusion disease and short bowel syndrome. No significant clinical or laboratory abnormalities were reported.
When does Jaguar Health plan to file its crofelemer application for microvillus inclusion disease?
Jaguar plans to file a New Drug Application in mid-2027 for microvillus inclusion disease as part of its intestinal failure development program.